The panel considers incumbent vendor Express Scripts, Inc.'s appeal of the Acting Director of the Division of Purchase and Property's final agency decision sustaining the Division's award of a three-year contract for Pharmacy Benefit Management to OptumRx, Inc. Although anticipated changes in Plan Design affecting the Contract make the question more difficult than it might otherwise appear, we conclude Optum's statement "reserv[ing] the right to modify Financial Contracted Terms based on changes by the State in formulary or any carve out of services set forth in the Agreement, including but not limited to Specialty Pharmacy services," constitutes a substantial deviation from a material, non-waivable price term in the Solicitation and thus reverse the decision of the Acting Director and order the Contract rebid as expeditiously as possible. Whether that can occur in sufficient time to allow the Vendor to prepare for open enrollment next October is a matter we leave to the Acting Director.